AZCERT's Scientific Review Committee has reviewed available evidence for Remdesivir, an antiviral drug used to treat COVID-19, and found that its use is associated with the development of QTc prolongation. This analysis failed to find compelling evidence for a risk of torsades de pointes (TdP) arrhythmia. Therefore, Remdesivir has been added to the QTdrugs List in the Possible Risk of TdP category.
The Committee has also added Serdexmethylphenidate, a new prodrug of dexmethylphenidate used to treat ADHD, to the List of Drugs to Avoid (DTA List) in patients with congenital Long QT Syndrome because of its adrenaline-like properties.
We encourage all registered users to subscribe to our Newsletter so they can receive email notification when the QTdrugs List or DTA List has been revised. Simply log in to the CredibleMeds website and click on ACCOUNT SETTINGS, then click on Update Account Details to subscribe to our Newsletter. AZCERT will not share your information or use it for any other purpose.